Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. West on FDA Approval of Afatinib in NSCLC With Rare EGFR Mutations

January 15th 2018

H. Jack West, MD, thoracic oncologist, Swedish Cancer Institute of Swedish Medical Center, discusses the FDA approval of afatinib (Gilotrif) for the frontline treatment of patients with metastatic non

FDA Expands Afatinib's Approval for Lung Cancer

January 14th 2018

The FDA has expanded the frontline indication for afatinib to include the treatment of patients with metastatic non–small cell lung cancer whose tumors harbor uncommon EGFR alterations in L861Q, G719X, and/or S768I.

FLAURA Findings, Emerging Combos Advance EGFR+ NSCLC Landscape

January 11th 2018

Lecia V. Sequist, MD, reflects on the practice-changing osimertinib data, ongoing trials exploring combination regimens, and discusses the potential for immunotherapy in EGFR-positive NSCLC.

Finding the Best Spot for PD-1/PD-L1 Antibodies in Advanced Lung Cancer

January 11th 2018

Amid rapid-fire developments in non–small cell lung cancer (NSCLC) research, the role of checkpoint immunotherapy continues to mature.

Dr. West Discusses Chemotherapy Without Driver Mutations in NSCLC

January 11th 2018

H. Jack West, MD, thoracic oncologist, Swedish Cancer Institute at Swedish Medical Center, discusses chemotherapy in patients with non

Evidence Builds for Immunotherapy Combos in SCLC

January 10th 2018

Increasing evidence suggests that immune responses against SCLC cells make immunotherapy a rational approach.

Expert Discusses Treatment Advances in ALK-Positive NSCLC

January 9th 2018

Erminia Massarelli, MD, PhD, discusses the evolving paradigm of ALK-positive non-small cell lung cancer based on recent regulatory decisions and what additional advancements are expected in the year ahead.

Neoadjuvant Immunotherapy Being Investigated in Early-Stage NSCLC

January 8th 2018

Jae Y. Kim, MD, discusses developments with checkpoint inhibition in patients with resectable NSCLC.

Dr. Paik Discusses Advances in Squamous Cell Lung Cancer

January 6th 2018

Paul K. Paik, MD, clinical director, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, discusses recent advancements in squamous cell lung cancer.

Biomarkers in NSCLC Poised to Expand in Coming Years

January 5th 2018

Ravi Salgia, MD, PhD, discusses the evolution and current state of biomarker testing in the field of NSCLC.

Treatment Paradigm Evolving in Early-Stage Lung Cancer

January 4th 2018

Dan J. Raz, MD, discusses the ongoing ALCHEMIST trial and some novel techniques, such as tissue slice culture, that are propelling the field of lung cancer forward.

Plinabulin Combo With Docetaxel Aimed at Delivering a "Double Hit" in NSCLC Trial

January 3rd 2018

Plinabulin, an antineoplastic agent that activates an immune response, is being investigated as a treatment option for patients with advanced or metastatic non–small cell lung cancer who have progressed after standard-of-care therapy.

Dr. Salgia on Next-Generation Sequencing in Lung Cancer

January 2nd 2018

Ravi Salgia, MD, PhD, Arthur & Rosalie Kaplan Chair in Medical Oncology, associate director for clinical sciences at City of Hope, discusses the importance of next-generation sequencing for patients with lung cancer.

Expert Assesses Challenges of Disparity in Lung Cancer

January 2nd 2018

Loretta Erhunmwunsee, MD, discusses the racial and socioeconomic disparities in lung cancer trials

Reckamp Recounts Recent Lung Cancer Advances

January 2nd 2018

Karen Reckamp, MD, discusses positive phase III data, recent regulatory approvals, and what research the new year is likely to bring to the field of non-small cell lung cancer (NSCLC).

Liquid Biopsies a Quicker Alternative to Standard Approaches in NSCLC

January 1st 2018

Jared Weiss, MD, discusses utilizing liquid biopsies for patients with lung cancer, the pros and cons of the approach, and when it might be appropriate to rebiopsy patients.

Dr. Levy on the Treatment of T790M-Mutant Lung Cancer

December 29th 2017

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses the treatment options for patients with T790M-mutant lung cancer.

Dr. Reckamp on Molecular Testing in Lung Cancer

December 28th 2017

Karen Reckamp, MD, MS, medical oncologist, City of Hope, discusses the role of molecular testing for patients with lung cancer.

Biomarker Testing Continues to Develop in NSCLC

December 28th 2017

Kathryn F. Mileham, MD, discusses the development of biomarker testing for patients with mutated non-small cell lung cancer.

Various Immunotherapy Combinations Continue to Be Explored in NSCLC

December 28th 2017

Daniel E. Haggstrom, MD, discusses the developing area of immunotherapy combinations for patients with non-small cell lung cancer.